Search bioRxiv⌕ Search

Biology subjects

Arefiev, I.

Publications and source records attributed to Arefiev, I..

3 recordsLinked to original sources

More is better: A simple antibody-based strategy for recovering all major mouse brain cell types from multiplexed single-cell RNAseq samples.

Single-cell RNA sequencing (scRNAseq) is a powerful yet costly technique for studying cellular diversity within the complexity of organs and tissues. Here, we sought to establish an effective multiplexing strategy for the adult mouse brain that could allow multiple experimental groups to be pooled into a single sample for sequencing, reducing costs, increasing data yield, and eliminating batch effects. We first describe an optimized cold temperature single-cell dissociation protocol that permits isolation of a high yield and viability of brain cells from the adult mouse. Cells isolated using this protocol were then screened by flow cytometry using a panel of antibodies, allowing identification of a single antibody, anti-Thy1.2, that can tag the vast majority of isolated mouse brain cells. We then used this primary antibody against a "universal" neural target, together with secondary antibodies carrying sample-specific oligonucleotides and the BD Rhapsody single-cell system and show that multiple adult mouse brain samples can be pooled into a single multiplexed run for scRNAseq. Bioinformatic analyses enable efficient demultiplexing of the sequenced pooled brain sample, with high tagging efficiency and precise annotation and clustering of brain cell populations. The efficiency and flexibility of the cell dissociation protocol and the two-step multiplexing strategy simplifies experimental design, optimizes reagent usage, eliminates sequencing batch effects and reduces overall experimental costs.

molecular biology↗

Analysis of Mutations in Precision Oncology using The Automated, Accurate, and User-Friendly Web Tool PredictONCO

Next-generation sequencing technology has created many new opportunities for clinical diagnostics, but it faces the challenge of functional annotation of identified mutations. Various algorithms have been developed to predict the impact of missense variants that influence oncogenic drivers. However, computational pipelines that handle biological data must integrate multiple software tools, which can add complexity and hinder non-specialist users from accessing the pipeline. Here, we have developed an online user-friendly web server tool PredictONCO that is fully automated and has a low barrier to access. The tool models the structure of the mutant protein in the first step. Next, it calculates the protein stability change, pocket level information, evolutionary conservation, and changes in ionisation of catalytic amino acid residues, and uses them as the features in the machine-learning predictor. The XGBoost-based predictor was validated on an independent subset of held-out data, demonstrating areas under the receiver operating characteristic curve (ROC) of 0.95 and 0.94, and the average precision from the precision-recall curve 0.98 and 0.94 for structure-based and sequence-based predictions, respectively. Finally, PredictONCO calculates the docking results of small molecules approved by regulatory authorities. We demonstrate the applicability of the tool by presenting its usage for variants in two cancer-associated proteins, cellular tumour antigen p53 and fibroblast growth factor receptor FGFR1. Our free web tool will assist with the interpretation of data from next-generation sequencing and navigate treatment strategies in clinical oncology: https://loschmidt.chemi.muni.cz/predictonco/.

bioinformatics↗

A Computational Workflow for Analysis of Missense Mutations in Precision Oncology

Every year, more than 19 million cancer cases are diagnosed, and this number continues to increase annually. Since standard treatment options have varying success rates for different types of cancer, understanding the biology of an individuals tumour becomes crucial, especially for cases that are difficult to treat. Personalised high-throughput profiling, using next-generation sequencing, allows for a comprehensive examination of biopsy specimens. Furthermore, the widespread use of this technology has generated a wealth of information on cancer-specific gene alterations. However, there exists a significant gap between identified alterations and their proven impact on protein function. Here, we present a bioinformatics pipeline that enables fast analysis of a missense mutations effect on stability and function in known oncogenic proteins. This pipeline is coupled with a predictor that summarises the outputs of different tools used throughout the pipeline, providing a single probability score, achieving the balanced accuracy above 86%. The pipeline incorporates a virtual screening method to suggest potential FDA/EMA-approved drugs to be considered for treatment. We showcase three case studies to demonstrate the timely utility of this pipeline. To facilitate access and analysis of cancer-related mutations, we have packaged the pipeline as a web server, which is freely available at https://loschmidt.chemi.muni.cz/predictonco/.

cancer biology↗